Primary Hyperoxaluria Type 1 (PH1)
7 clinical trials · Condition
◉ Watch Primary Hyperoxaluria Type 1 (PH1)
| Record | Firm | Date |
|---|---|---|
| A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2 (NCT03847909) | Novo Nordisk A/S | 2019-10-28 |
| Long Term Extension Study in Patients With Primary Hyperoxaluria (NCT04042402) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2019-07-09 |
| A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (NCT03905694) | Alnylam Pharmaceuticals | 2019-04-22 |
| A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 (NCT03681184) | Alnylam Pharmaceuticals | 2018-11-27 |
| Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 (NCT02706886) | Alnylam Pharmaceuticals | 2016-03-08 |
| Treatment of Primary Hyperoxaluria Type 1 With Nedosiran (NCT05993416) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company |
Track Primary Hyperoxaluria Type 1 (PH1) automatically
Every clearance here is in the API, with alerts when new ones post.